Table 1 |
||||
|
Rates of HIV-1 infections in the vaccinees and in placebo inoculated volunteers enrolled in the STEP vaccine trial. |
||||
| No immunity to Ad5 (< 18 units) |
Medium immunity to Ad5 (18–200 units) |
High immunity to Ad5 (201–1000 units) |
Very high immunity to Ad5 (> 1000 units) |
|
|
|
||||
| Vaccinea |
20 infected out of 382 total |
8 infected out of 140 total |
14 infected out of 229 total |
7 infected out of 163 total |
| Placebob |
20 infected out of 394 total |
4 infected out of 142 total |
7 infected out of 229 total |
2 infected out of 157 total |
|
|
||||
|
a. Subjects were inoculated with three rAD5 vectors expressing gag, pol or nef coding sequences. b. Control subjects were inoculated with an inactive substance (saline). Immunity to Ad5 vector was assessed by ELISA titers of the antibody response to the rAd5 vector. |
||||
|
Iaccino et al. Retrovirology 2008 5:56 doi:10.1186/1742-4690-5-56 |
||||
